



GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

REGD. OFFICE & FACTORY: 69/C GIDC INDUSTRIAL ESTATE,
VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA
TEL: 0260-2430027 / 2400639
E-mail: hrm@gtbl.in

GTBL/BSE/NSE/2025-26/24

12th September, 2025

The Manager
Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code – 506879

The Manager – Listing Department
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400051
Symbol: GUJTHEM

Dear Sir / Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform you that the members of the Company inter-alia have approved the following items:

1. Dividend of Re. 0.67 i.e. @ 67% per equity share having face value of Re.1/- each aggregating to Rs.7,30,06,728 for the Financial Year ended 31st March, 2025.
2. Appointment of M/s. KRS AND CO., Practicing Company Secretaries, represented by CS Ketan Ravindra Shirwadkar (Membership No. A37829, COP No. 15386), as the Secretarial Auditor of the Company, to hold office for a term of five (5) consecutive financial years commencing from the financial year ending 31st March, 2026 up to the financial year ending 31st March, 2030.
3. Appointment and re-designation of Dr. Sachin D. Patel (DIN: 00033353) as Managing Director of the Company for a period of 5 (five) years with effect from 1st July, 2025.
4. Appointment of Mr. Nihar Ajay Parikh (DIN: 02475787) as an Independent Director of the Company with effect from 1st August, 2025 till 31st July, 2030 and he shall not be liable to retire by rotation.

The detailed disclosures on item no. 3 & 4 is given in Annexure A attached herewith.

For Gujarat Themis Biosyn Limited

Vineet Gawankar
Company Secretary & Compliance Officer



GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

REGD. OFFICE & FACTORY: 69/C GIDC INDUSTRIAL ESTATE,
VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA
TEL: 0260-2430027 / 2400639
E-mail: hrm@gtbl.in

Annexure – A

Disclosure under sub-para (7) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 on items:-

1. Appointment and re-designation of Dr. Sachin D. Patel as Managing Director of the Company.

Sr. No.	Particulars	Details of Change
1	Reason for change	Appointment and re-designation as Managing Director of the Company subject to shareholders approval.
2	Date of appointment	Appointment with effect from 1 st July, 2025 till 30 th June, 2030.
3	Brief Profile (in case of appointment)	Dr. Sachin Patel holds a Doctorate in Pharmacy and possesses over 20 years of experience in pharmaceutical business covering product development, marketing, regulatory affairs, strategic management and corporate leadership. He has played a pivotal role in driving value creation and enhancing operational capabilities in various entities of the Themis group.
4	Relationships with other Directors (in case of appointment)	Dr. Sachin Patel is the son of Dr. Dinesh S. Patel, Chairman of the Company.
5	Affirmation	Dr. Sachin D. Patel is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority. He has not been convicted of any offence in connection with the promotion, formation or management of any company or LLP, nor found guilty of any fraud, misfeasance or breach of duty to any company under the Companies Act, 2013 or any previous Companies Act in the last five years.



GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

REGD. OFFICE & FACTORY: 69/C GIDC INDUSTRIAL ESTATE,
VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA

TEL: 0260-2430027 / 2400639

E-mail: hrm@gtbl.in.net

2. Appointment of Mr. Nihar Parikh (DIN:02475787) as an Independent Director of the Company:

Sr. No	Particulars	Details of Change
1.	Reason for change	Appointment as an Independent Director.
2.	Date of Appointment	1 st August, 2025
3.	Brief Profile	<p>Mr. Nihar Parikh is an entrepreneur turned Venture Capitalist. He served as the Chief Executive Officer of ZCL Chemicals Limited (Zandu), where he successfully led the company through a transformative growth phase culminating in its sale. Post this exit, Mr. Parikh transitioned into the health-tech venture capital space and is currently the founder of 4Point0 Health Ventures, a fund focused on early-stage health-tech startups in India.</p> <p>His prior experience also includes leadership roles in his family office, global exposure at Janssen Pharmaceutical (a Johnson & Johnson company in Belgium), and academic grounding in Bachelor of Engineering (BE), Chemical Engineering from the University of Mumbai. Mr. Parikh is known for his strategic acumen, entrepreneurial mindset and ability to scale innovation-driven businesses.</p>
4.	Disclosure of relationship between Directors (in case of appointment)	No relationship with the Directors of the Company
5	Affirmation	Mr. Nihar Parikh is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority. He has not been convicted of any offence in connection with the promotion, formation or management of any company or LLP, nor found guilty of any fraud, misfeasance or breach of duty to any company under the Companies Act, 2013 or any previous Companies Act in the last five years.